Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00577122 · ClinicalTrials.gov registry record · Phase 2
Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
A Phase 2 study of Stage IV Breast Cancer and Recurrent Breast Cancer, sponsored by Indiana University.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 7
- Study locations
NCT00577122 is a Phase 2 study of Stage IV Breast Cancer and Recurrent Breast Cancer that has completed, run by Indiana University. The registered enrollment target is 30 participants, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (55% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT00577122, a Phase 2 study of Stage IV Breast Cancer and Recurrent Breast Cancer, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to evaluate the impact of MPA alone and in combination with low dose oral chemotherapy in patients with ER- and PR- advanced breast cancer.
Conditions Studied
Interventions
- DRUG Medroxyprogesterone progesterone acetate (MPA)
- DRUG Medroxyprogesterone with Cyclophosphamide + Methotrexate
Study Locations (7)
North Carolina
- University of North Carolina, Lineberger Comprehensive Cancer Center - Chapel Hill
- Duke University Comprehensive Cancer Center - Durham
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California, San Francisco Comprehensive Cancer Center - San Francisco
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Massachusetts
- Dana-Farber Cancer Institute - Boston
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00577122
The ClinicalTrials.gov registry entry for NCT00577122 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (55% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stage IV Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Medroxyprogesterone progesterone acetate (MPA) is the first listed.
NCT00577122 reports 7 study locations spanning 6 distinct geographic areas - top geographies include North Carolina, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT00577122 about?
NCT00577122 is a clinical study titled "Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer". The purpose of this study is to evaluate the impact of MPA alone and in combination with low dose oral chemotherapy in patients with ER- and PR- advanced breast cancer.
What is the current status of trial NCT00577122?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2007-07. Estimated completion is 2011-12.
What conditions does trial NCT00577122 study?
This clinical trial studies the following conditions: Stage IV Breast Cancer, Recurrent Breast Cancer, Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer.
What interventions are being tested in trial NCT00577122?
The interventions under investigation include: Medroxyprogesterone progesterone acetate (MPA) (DRUG), Medroxyprogesterone with Cyclophosphamide + Methotrexate (DRUG).
Who is sponsoring clinical trial NCT00577122?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00577122 being conducted?
This trial has 7 study locations across Alabama, California, Indiana, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
RECRUITING · Phase 2
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
COMPLETED · Phase 2
-
Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.